Hyderabad-based Dr. Reddy's Laboratories saw its shares climb by 2% on Friday following the announcement of an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited. The partnership grants Dr. Reddy's sole rights for Takeda's QDENGA dengue vaccine within India's private healthcare market, covering both pediatric and adult vaccination.
Strategic Partnership to Combat Dengue Burden
Under the terms of the agreement, Dr. Reddy's will manage the distribution and marketing of QDENGA across India's private sector. Takeda, a global biopharmaceutical leader, will retain commercialization rights for the vaccine in the public market and will continue to oversee its manufacturing and importation into the country. This strategic collaboration aims to address the significant public health challenge posed by dengue fever in India, where reported cases have surged eleven-fold over the past two decades.
QDENGA: A Crucial New Vaccine for India
The QDENGA vaccine, a live-attenuated tetravalent dengue vaccine, offers protection against all four dengue virus serotypes, which are known to circulate concurrently across various regions of India. It is administered as a two-dose regimen, with doses spaced three months apart. The Central Drugs Standard Control Organization (CDSCO) granted marketing authorization for QDENGA in July 2026, approving its use for individuals aged 4 to 60 years. The vaccine is anticipated to become available in India during the first half of 2027, pending local regulatory processes.
The vaccine's development included a comprehensive clinical program involving over 60,000 participants. Notably, the Phase 3 TIDES trial demonstrated efficacy across all four serotypes for a period of up to seven years. Globally, QDENGA has received approvals in 43 countries since 2022 and has seen over 32 million doses distributed worldwide. It is also included in the World Health Organization (WHO) List of Prequalified Vaccines, underscoring its recognized safety and efficacy standards.
Market Reaction and Future Outlook
Investors reacted positively to the news, pushing Dr. Reddy's Laboratories shares to an intraday high of Rs 1,193.40 on Friday, up from its previous close of Rs 1,172.05. This partnership positions Dr. Reddy's at the forefront of providing an essential new tool in India's fight against dengue, a disease that continues to place a substantial burden on the country's healthcare system and economy.